Statements

CSRxP Commends Congressional Probe Of Big Pharma Giant’s Anti-Competitive Tactics and Egregious Pricing Practices

Sep 1, 2020

U.S. House Oversight Committee Subpoena of AbbVie Related to Pricing of Read More

CSRXP APPLAUDS INCLUSION OF CREATES IN SPENDING DEAL; URGES CONGRESS TO KEEP WORKING TO HOLD BIG PHARMA ACCOUNTABLE, LOWER Rx PRICES

Dec 16, 2019

Passage of Bipartisan, Market-based CREATES Act Will Be A First Step in the Read More

CSRXP APPLAUDS USMCA CHANGES TO PUT AMERICAN PATIENTS FIRST

Dec 10, 2019

Revisions to Historic Trade Deal Remove Big Pharma Carveout Washington Read More

CSRxP Commends Administration for Commitment to DTC Advertising Rule

Aug 21, 2019

Applauds HHS For Appealing Ruling Against List Price Transparency Measure Read More

Insulin Hearing Will Add To Drug Pricing Momentum On Capitol Hill 

Apr 1, 2019

CSRxP Commends House Energy & Commerce Committee For Giving Voice To Read More

CSRxP Statement on Potential Big Pharma Bailout

Sep 21, 2018

“Only Big Pharma would use bipartisan opioid legislation as another Read More

CSRxP Statement On Exclusion Of Big Pharma Accountability Amendment In Appropriations Bill

Sep 13, 2018

House Misses Bipartisan Opportunity To Hold Big Pharma Accountable Read More

CSRxP Urges FDA To Finalize Guidance Critical To Lower Drug Prices

Aug 23, 2018

The Campaign for Sustainable Rx Pricing (CSRxP) today joined more than a dozen Read More

CSRxP Applauds Trump Administration’s Focus on Out-of-Control Drug Prices

Aug 21, 2018

CSRxP spokesman Will Holley released the following statement applauding the Read More

CSRxP Letter of Support for Durbin-Grassley DTC Advertising Amendment

Aug 21, 2018

Last night, Senators Durbin and Grassley filed an amendment to the Labor-HHS Read More

CSRxP Statement on CMS Changes to Medicare Part B

Aug 7, 2018

CSRxP spokesman Will Holley released the following statement following Read More

New Report Demonstrates Big Pharma’s Abuses of the Patent System

Aug 2, 2018

CSRxP spokesman Will Holley released the following statement on the release of Read More